Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006211 · ClinicalTrials.gov registry record · Phase 2
A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments
A Phase 2 study, sponsored by Agouron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
NCT00006211 is a Phase 2 study that has completed, run by Agouron Pharmaceuticals. The registered enrollment target is 350 participants.
The verdict
NCT00006211, a Phase 2 study, has completed, sponsored by Agouron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the addition of capravirine to VIRACEPT (nelfinavir mesylate) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is an effective combination drug therapy for HIV patients who have failed a nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy.
Interventions
- DRUG Nelfinavir mesylate
- DRUG Capravirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2000-02 |
| Est. Completion | 2001-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006211
The ClinicalTrials.gov registry entry for NCT00006211 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agouron Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nelfinavir mesylate is the first listed.
NCT00006211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006211 about?
NCT00006211 is a clinical study titled "A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments". The purpose of this study is to see if the addition of capravirine to VIRACEPT (nelfinavir mesylate) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is an effective combination drug therapy for HIV patients who have failed a nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy.
What is the current status of trial NCT00006211?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2000-02. Estimated completion is 2001-04.
What interventions are being tested in trial NCT00006211?
The interventions under investigation include: Nelfinavir mesylate (DRUG), Capravirine (DRUG).
Who is sponsoring clinical trial NCT00006211?
This trial is sponsored by Agouron Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.